First-in-Human Phase 1 Randomized Trial with the Anti-CD40 Monoclonal Antibody KPL-404: Safety, Tolerability, Receptor Occupancy, and Suppression of T-Cell-Dependent Antibody Response

Manoj Samant; John Ziemniak; John F Paolini

doi:10.1124/jpet.123.001771

OtherInflammation, Immunopharmacology, and Asthma

First-in-Human Phase 1 Randomized Trial with the Anti-CD40 Monoclonal Antibody KPL-404: Safety, Tolerability, Receptor Occupancy, and Suppression of T-Cell-Dependent Antibody Response

Manoj Samant, John Ziemniak and John F Paolini

Journal of Pharmacology and Experimental Therapeutics September 12, 2023, JPET-AR-2023-001771; DOI: https://doi.org/10.1124/jpet.123.001771

Manoj Samant

1Kiniksa Pharmaceuticals, United States

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

John Ziemniak

1Kiniksa Pharmaceuticals, United States

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

John F Paolini

1Kiniksa Pharmaceuticals, United States

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: jpaolini@kiniksa.com

Article
Figures & Data
Info & Metrics
eLetters
PDF + SI
PDF

Article Figures & Data

Additional Files

Data Supplement

Supplemental Data -
APPENDIX S1. Inclusion and exclusion criteria for study participants.

APPENDIX S2. Supplemental methods for KPL-404 serum and whole blood assays.

APPENDIX S3. Noncompartmental Parameter PK Supportive Information.

PreviousNext

In this issue

Journal of Pharmacology and Experimental Therapeutics

Vol. 387, Issue 1

1 Oct 2023

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Editorial Board (PDF)
Front Matter (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following First-in-Human Phase 1 Randomized Trial with the Anti-CD40 Monoclonal Antibody KPL-404: Safety, Tolerability, Receptor Occupancy, and Suppression of T-Cell-Dependent Antibody Response

Message Subject (Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics

Message Body (Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

OtherInflammation, Immunopharmacology, and Asthma

First-in-Human Phase 1 Trial with KPL-404

Manoj Samant, John Ziemniak and John F Paolini

Journal of Pharmacology and Experimental Therapeutics September 12, 2023, JPET-AR-2023-001771; DOI: https://doi.org/10.1124/jpet.123.001771

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

OtherInflammation, Immunopharmacology, and Asthma

First-in-Human Phase 1 Trial with KPL-404

Manoj Samant, John Ziemniak and John F Paolini

Journal of Pharmacology and Experimental Therapeutics September 12, 2023, JPET-AR-2023-001771; DOI: https://doi.org/10.1124/jpet.123.001771

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
Figures & Data
Info & Metrics
eLetters
PDF + SI
PDF

Main menu

User menu

Search

First-in-Human Phase 1 Randomized Trial with the Anti-CD40 Monoclonal Antibody KPL-404: Safety, Tolerability, Receptor Occupancy, and Suppression of T-Cell-Dependent Antibody Response

Article Figures & Data

Additional Files

Data Supplement

In this issue

First-in-Human Phase 1 Trial with KPL-404

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Navigate

More Information

ASPET's Other Journals